Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AbbVie reported its first-quarter 2023 financial results with a GAAP diluted EPS of $0.13, down 94.8% from the previous year, and an adjusted diluted EPS of $2.46, a decrease of 22.2%. Net revenues fell 9.7% to $12.225 billion, with notable declines in its Immunology and Hematologic Oncology portfolios. Humira revenue plunged 25.2% to $3.541 billion, while Skyrizi and Rinvoq saw increases of 44.7% and 47.5%, respectively. A full-year 2023 adjusted EPS guidance was raised to a range of $10.72 - $11.12, excluding future IPR&D impacts. Significant events included the approval of Rinvoq for Crohn's disease and positive Skyrizi trial results, but AbbVie also announced the withdrawal of certain U.S. approvals for Imbruvica.
AbbVie has announced positive results from its Phase 3 ELEVATE study of atogepant, evaluating its effectiveness for preventing episodic migraines in patients who have previously failed multiple oral medications. The study showed a statistically significant reduction in mean monthly migraine days (MMDs) of 4.20 days for those taking atogepant 60 mg once daily, compared to a 1.85-day reduction in the placebo group (p<0.0001). This study included 309 participants, with 56% having failed two classes of preventive medications, and demonstrated that atogepant was well tolerated, consistent with its safety profile. The results will be presented at the American Academy of Neurology Annual Meeting on April 25, 2023.
Summary not available.
AbbVie announced that the FDA has approved QULIPTA® (atogepant) for the preventive treatment of chronic migraine in adults, making it the first and only oral CGRP receptor antagonist for this purpose.
This expanded indication offers a new treatment option for those suffering from chronic migraines, defined as experiencing headaches on 15 or more days per month.
The approval follows a Phase 3 clinical trial demonstrating a statistically significant reduction in average monthly migraine days and improvements in overall functioning.
AbbVie notably holds a competitive edge with three prescription treatments for migraine, including QULIPTA, BOTOX® (for chronic migraine), and UBRELVY® (for acute migraine attacks).
AbbVie announced the European Commission's approval of RINVOQ (upadacitinib) as the first oral Janus Kinase (JAK) inhibitor for treating adults with moderately to severely active Crohn's disease. This marks the seventh approved indication for RINVOQ in the EU and the third for AbbVie's inflammatory bowel disease portfolio within a year. RINVOQ demonstrated significant efficacy in achieving clinical and endoscopic remission in clinical trials compared to placebo, with 35%-51% of patients achieving remission at 12 weeks. Safety data indicated results consistent with RINVOQ's known profile, with no new safety concerns reported. This approval may enhance AbbVie's market position in the ongoing treatment of inflammatory bowel diseases.